Loading clinical trials...
Loading clinical trials...
A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects With Severe Sepsis
Conditions
Interventions
BMS-936559
Placebo
Locations
13
United States
Uc Davis Medical Center
Sacramento, California, United States
Local Institution
Denver, Colorado, United States
University Of Florida
Gainesville, Florida, United States
Emory University
Atlanta, Georgia, United States
Osf Saint Francis Medical Center
Peoria, Illinois, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
December 2, 2015
Primary Completion Date
March 15, 2017
Completion Date
March 15, 2017
Last Updated
September 15, 2017
NCT07550400
NCT07230041
NCT07367113
NCT04955210
NCT07179276
NCT06709573
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions